Karma Biotechnologies
Biotechnology ResearchUnited States2-10 Employees
Karma is a proud IndieBio company! We're thrilled to be in the current IBSF14 cohort. Metastatic cancer can be cured by cytokine immunotherapies, but only for a lucky few (about 7% of patients). Karma is making these medicines safe and effective for the other 93% by engineering immune cells to manufacture cytokines and other biologicals locally within the tumor, exactly where they're needed.